Learning from aprotinin--mandatory trials of comparative efficacy and safety needed.
Ray
Wayne A
WA
D000933:Antifibrinolytic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007611:Aprotinin / Q000009:adverse effects* / Q000627:therapeutic use; D001026:Coronary Artery Bypass; D006801:Humans; D009026:Mortality; D011358:Product Surveillance, Postmarketing; D016032:Randomized Controlled Trials as Topic
D000933:Antifibrinolytic Agents; D007611:Aprotinin